Can-Fite Biopharma Ltd
Research Can-Fite Biopharma Ltd (CANF) on Bullrun: market cap USD 4.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCANF
- ExchangeNYSE MKT
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.35M
- Financial periodFY2025
- RevenueUSD 405.00K
- Revenue growth-39.9%
- Net income-USD 9.83M
- Free cash flow-USD 8.95M
Valuation Snapshot
latest market cap is USD 4.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 405.00K | -USD 9.83M | -USD 8.95M | n/a | -5.97 | USD 5.53M | USD 71.00K | USD 5.59M |
| FY2024 | USD 674.00K | -USD 7.88M | -USD 7.64M | n/a | -10.86 | USD 4.83M | USD 104.00K | USD 5.44M |
| FY2023 | USD 743.00K | -USD 7.63M | -USD 8.44M | n/a | -17.92 | USD 4.28M | USD 40.00K | USD 6.24M |
| FY2022 | USD 810.00K | -USD 10.17M | -USD 10.81M | n/a | -0.01 | USD 2.98M | USD 62.00K | USD 4.47M |
| FY2021 | USD 853.00K | -USD 12.62M | -USD 9.87M | n/a | -0.03 | USD 4.39M | n/a | USD 14.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.35M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.41M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.21M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 8.98M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.59M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 35.09M | n/a | n/a | n/a |
About Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Can-Fite Biopharma Ltd's market cap?
Can-Fite Biopharma Ltd's market capitalization is USD 4.35M.
What does Can-Fite Biopharma Ltd do?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.